在挪威监狱中被监禁的人群中感染C型肝炎
J Hauge1,2, K B Kielland1, E Opheim3,4
1Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Hamar, Norway.
Scandinavian journal of gastroenterology
|February 3, 2026
概括
型肝炎病毒 (HCV) 感染影响了挪威监狱中十分之一的新入狱者. 早期的HCV检测和治疗对于这种脆弱人群至关重要.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 在被监禁人群中,肝炎C病毒 (HCV) 感染的高患病率,特别是在注射毒品的人群中 (PWID).
- 需要评估挪威监狱内的HCV感染率.
研究的目的:
- 确定挪威监狱新入狱人员中HCV感染的流行率.
- 在这种环境中,特别关注注射毒品 (PWID) 的人群中HCV感染率.
主要方法:
- 在6个挪威监狱连续招收新入狱者.
- 在监禁后两周内检测抗HCV抗体和HCVRNA.
- 收集人口,社会和药物使用行为数据.
主要成果:
- 总体抗HCV流行率为19.7% (171/870) 和HCVRNA流行率为9.3% (81/870).
- 在注射药物使用者 (PWID) 中,抗HCV患病率为62.6% (164/262),HCVRNA患病率为30.2% (79/262).
- 分享针是抗HCV阳性的唯一独立预测因素 (调整后OR为3.50).
结论:
- 在挪威,大约10%的新入狱者目前患有HCV感染.
- 建议在所有惩戒设施内实施快速HCV检测和治疗服务.
相关概念视频
The Stanford Prison Experiment
24.7K
The famous and controversial Stanford Prison Experiment, conducted by social psychologist Philip Zimbardo and his colleagues at Stanford University, demonstrated the power of social roles, social norms, and scripts.
24.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System
6.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
245
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
245
Hepatic Drug Excretion: Influencing Factors
589
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
589
Hepatic Drug Clearance: Role of Transporters
310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310


